HSA — authorised 27 December 1985
- Marketing authorisation holder: FOUGERA PHARMS
- Status: likely_approved
HSA authorised Temovate on 27 December 1985
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. HSA authorised it on 27 December 1985.
FOUGERA PHARMS holds the Singaporean marketing authorisation.